VectivBio AG

Vectiv Bio Ag

Biotechnology, Basel, New York, United States, 51-200 Employees

vectivbio.com

  • twitter
  • LinkedIn

phone no Phone Number: +19*********

Who is VECTIVBIO AG

VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed i...

Read More

map
  • Basel, New York, United States Headquarters: Basel, New York, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

checked-icon Does something look wrong? Fix it. | View contact records from VECTIVBIO AG

VectivBio AG Org Chart and Mapping

Employees

Robert Sklans

Vice President, Head of Us Human Resources

Paul Talierco

Vice President, Head Regulatory Affairs Cmc

Nader Youssef

Senior Vice President, Global Medical Affairs and Patient Partnership

Jeff Henderson

Vice President, Head of Global Market Access, Reimbursement, & Distribution

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding VectivBio AG

Answer: VectivBio AG's headquarters are located at Basel, New York, United States

Answer: VectivBio AG's phone number is +19*********

Answer: VectivBio AG's official website is https://vectivbio.com

Answer: VectivBio AG's revenue is Under $1 Million

Answer: VectivBio AG has 51-200 employees

Answer: VectivBio AG is in Biotechnology

Answer: VectivBio AG contact info: Phone number: +19********* Website: https://vectivbio.com

Answer: VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on peoples lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. The company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for Short Bowel Syndrome.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access